Phase I and pharmacokinetic study of OSI-211, a liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.

被引：0
|
作者：
Giles, F
Tallman, M
Garcia-Manero, G
Cortes, J
Thomas, D
Wierda, W
Verstovsek, S
Hamilton, M
Barrett, E
Albitar, M
Kantarjian, H
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[3] OSI Pharmaceut Inc, Boulder, CO USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4732
引用
收藏
页码：251B / 251B
页数：1
相关论文
共 50 条
  • [41] A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors
    Ueno, Hideki
    Kondo, Shunsuke
    Yoshikawa, Shusuke
    Inoue, Koichi
    Andre, Valerie
    Tajimi, Masaomi
    Murakami, Haruyasu
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 647 - 656
  • [42] PHASE-I AND PHARMACODYNAMIC STUDY OF THE TOPOISOMERASE I-INHIBITOR TOPOTECAN IN PATIENTS WITH REFRACTORY ACUTE-LEUKEMIA
    ROWINSKY, EK
    ADJEI, A
    DONEHOWER, RC
    GORE, SD
    JONES, RJ
    BURKE, PJ
    CHENG, YC
    GROCHOW, LB
    KAUFMANN, SH
    JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) : 2193 - 2203
  • [43] Clinical and pharmacokinetic study with liposomal doxorubicin (DL-1) in patients with advanced metastatic cancer -: results from a phase-I study
    Mross, K
    Gierlich, T
    Häring, B
    März, W
    Unger, C
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2002, 40 (08) : 387 - 388
  • [44] Phase I study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
    Vey, N
    Kantarjian, H
    Beran, M
    O'Brien, S
    Cortes, J
    Giles, FJ
    Cheson, B
    Arbuck, S
    Estey, E
    BLOOD, 1998, 92 (10) : 235A - 235A
  • [45] TLC388, a novel topoisomerase-1 inhibitor with antihypoxia inducible factor-1 alpha activity: A phase I and pharmacokinetic study in patients with advanced solid malignancies
    Lin, C.
    Ghamande, S. A.
    Dezube, B. J.
    Silverman, M. H.
    Fong, K.
    Kuo, M.
    Mach, W.
    Tseng, Y.
    Hsu, S.
    Goel, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours
    Evans, T. R. Jeffry
    Dean, Emma
    Molife, L. Rhoda
    Lopez, Juanita
    Ranson, Malcolm
    El-Khouly, Fatima
    Zubairi, Ishtiaq
    Savulsky, Claudio
    Reyderman, Larisa
    Jia, Yan
    Sweeting, Lorna
    Greystoke, Alastair
    Barriuso, Jorge
    Kristeleit, Rebecca
    BRITISH JOURNAL OF CANCER, 2019, 120 (04) : 379 - 386
  • [47] Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours
    T. R. Jeffry Evans
    Emma Dean
    L. Rhoda Molife
    Juanita Lopez
    Malcolm Ranson
    Fatima El-Khouly
    Ishtiaq Zubairi
    Claudio Savulsky
    Larisa Reyderman
    Yan Jia
    Lorna Sweeting
    Alastair Greystoke
    Jorge Barriuso
    Rebecca Kristeleit
    British Journal of Cancer, 2019, 120 : 379 - 386
  • [48] Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours
    M J A de Jonge
    S Kaye
    J Verweij
    C Brock
    S Reade
    M Scurr
    L van Doorn
    C Verheij
    W Loos
    C Brindley
    P Mistry
    M Cooper
    I Judson
    British Journal of Cancer, 2004, 91 : 1459 - 1465
  • [49] CHALLENGE IN THE PHARMACOKINETIC EVALUATION OF DTS-108, A NEW TOPOISOMERASE I INHIBITOR, IN PATIENTS WITH ADVANCED CARCINOMAS
    Mir, O.
    Faivre, S.
    Dreyer, C.
    Coriat, R.
    Bouattour, M.
    Goldwasser, F.
    Raymond, E.
    ANNALS OF ONCOLOGY, 2012, 23 : 167 - 167
  • [50] Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors
    Yamada, Y
    Tamura, T
    Yamamoto, N
    Shimoyama, T
    Ueda, Y
    Murakami, H
    Kusaba, H
    Kamiya, Y
    Saka, H
    Tanigawara, Y
    McGovren, JP
    Natsumeda, Y
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (02) : 173 - 182
12345